Role of CD30 targeting in malignant lymphoma

Current Treatment Options in Oncology

Volumn 15, Issue 2, 2014, Pages 210-225

  Kumar, Anita ^a   Younes, Anas ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Anaplastic large cell lymphoma; Antibody drug conjugate; Brentuximab vedotin; CD30; Hodgkin lymphoma

Indexed keywords

BENDAMUSTINE; BEXAROTENE; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; DACARBAZINE; DOXORUBICIN; GEMCITABINE; IRATUMUMAB; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AFM13; MONOCLONAL ANTIBODY CD30 I 131; MONOCLONAL ANTIBODY XMAB2513; NAVELBINE; PLACEBO; RADIOPHARMACEUTICAL AGENT; SGN 30; TEMSIROLIMUS; UNCLASSIFIED DRUG; VINBLASTINE; XMAB 2513; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CAC10-VCMMAE;

ALOPECIA; ANEMIA; ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DRUG APPROVAL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GERM CELL TUMOR; HISTORY OF MEDICINE; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOMATOID PAPULOSIS; MAST CELL LEUKEMIA; MELANOMA; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYCOSIS FUNGOIDES; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN LYMPHOMA; SKIN TINGLING; STEVENS JOHNSON SYNDROME; STRUCTURE ACTIVITY RELATION; SYSTEMIC MASTOCYTOSIS; T CELL LYMPHOMA; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; VIRUS INFECTION; ADOLESCENT; ADULT; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); FEMALE; GENE EXPRESSION REGULATION; IMMUNOLOGY; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; LYMPHOMA; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902361962     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-014-0275-7     Document Type: Article

References (64)

1. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed- Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66(4):848-58. (Pubitemid 15242469)
2. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 1982;299(5878):65-7. (Pubitemid 12049770)
3. Hecht TT, Longo DL, Cossman J, Bolen JB, Hsu SM, Israel M, et al. Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells. J Immunol. 1985;134(6):4231-6.
4. Schwarting R, Gerdes J, Durkop H, Falini B, Pileri S, Stein H. BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood. 1989;74(5):1678-89. (Pubitemid 19251546)
5. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 1992;68(3):421-7.
6. Fonatsch C, Latza U, Durkop H, Rieder H, Stein H. Assignment of the human CD30 (Ki-1) gene to 1p36. Genomics. 1992;14(3):825 -6.
7. Duckett CS, Gedrich RW, Gilfillan MC, Thompson CB. Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol. 1997;17(3):1535-42. (Pubitemid 27097383)
8. Duckett CS, Thompson CB. CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev. 1997;11(21):2810-21. (Pubitemid 27481682)
9. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood. 2000;96(13):4307-12.
10. Smith CA, Gruss HJ, Davis T, Anderson D, Farrah T, Baker E, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell. 1993;73(7):1349-60. (Pubitemid 23201148)
11. Younes A, Consoli U, Zhao S, Snell V, Thomas E, Gruss HJ, et al. CD30 ligand is expressed on resting normal and malignant human B lymphocytes. Br J Haematol. 1996;93(3):569-71. (Pubitemid 26168602)
12. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994;83(8):2045-56. (Pubitemid 24112714)
13. Bowen MA, Lee RK, Miragliotta G, Nam SY, Podack ER. Structure and expression of murine CD30 and its role in cytokine production. J Immunol. 1996;156(2):442-9. (Pubitemid 26028901)
14. Amakawa R, Hakem A, Kundig TM, Matsuyama T, Simard JJ, Timms E, et al. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell. 1996;84(4):551-62.
15. DeYoung AL, Duramad O, Winoto A. The TNF receptor family member CD30 is not essential for negative selection. J Immunol. 2000;165(11):6170-3.
16. Kurts C, Carbone FR, Krummel MF, Koch KM, Miller JF, Heath WR. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature. 1999;398(6725):341-4. doi:10.1038/18692.
17. Gaspal FM, Kim MY, McConnell FM, Raykundalia C, Bekiaris V, Lane PJ. Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T cell memory. J Immunol. 2005;174(7):3891-6. (Pubitemid 40395961)
18. Gerli R, Lunardi C, Vinante F, Bistoni O, Pizzolo G, Pitzalis C. Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol. 2001;22(2):72-7. (Pubitemid 32667524)
19. Sun X, Somada S, Shibata K, Muta H, Yamada H, Yoshihara H, et al. A critical role of CD30 ligand/ CD30 in controlling inflammatory bowel diseases in mice. Gastroenterology. 2008;134(2):447-58. doi:10.1053/j.gastro.2007.11.004.
20. Sun X, Yamada H, Shibata K, Muta H, Tani K, Podack ER, et al. CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses. J Immunol. 2010;185(12):7671-80. doi:10.4049/jimmunol.1002229.
21. Blazar BR, Levy RB, Mak TW, Panoskaltsis-Mortari A, Muta H, Jones M, et al. CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus- host disease. J Immunol. 2004;173(5):2933-41. (Pubitemid 39141997)
22. Dai Z, Li Q, Wang Y, Gao G, Diggs LS, Tellides G, et al. CD4+ CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism. J Clin Invest. 2004;113(2):310-7. doi:10.1172/JCI19727. (Pubitemid 38544215)
23. Younes A, Carbone A. CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders. Int J Biol Markers. 1999;14(3):135-43. (Pubitemid 29495742)
24. Durkop H, Foss HD, Eitelbach F, Anagnostopoulos I, Latza U, Pileri S, et al. Expression of the CD30 antigen in non-lymphoid tissues and cells. J Pathol. 2000;190(5):613 - 8. doi:10.1002/(SICI)1096-9896(200004)190:5G613::AIDPATH55993. 0.CO;2-0.
25. Younes A, Kadin ME. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol. 2003;21(18):3526-34. doi:10.1200/JCO.2003.09.037. (Pubitemid 46594087)
26. de Leval L, Gaulard P. CD30+ lymphoproliferative disorders. Haematologica. 2010;95(10):1627-30. doi:10.3324/haematol.2010.029256.
27. Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121(14):2715-24. doi:10.1182/blood-2012-10-461848.
28. Collie AMG HB, Manilich EA, et al. CD30 Immunohistochemical expression in diffuse large B-cell lymphoma is associated with decreased overall survival and the non-germinal center molecular subtype. Blood (ASH Annual Meeting Abstracts) 2013; 122 (21).
29. Slack G SC, Sehn LH, Gascoyne RD. CD30 Expression in diffuse large B-cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2012; 120 (Abstract 1558).
30. Malamut G VV, Derrieux C, et al. Enteropathy-associated T-cell lymphoma type I, but not refractory celiac disease, strongly expresses CD30 and might benefit from brentuximab vedotin. Blood (ASH Annual Meeting Abstracts) 2013; 122 (21).
31. Lunning MA CA, Feldstein JT, et al. CD30 Is a potential therapeutic target in patients with HTLV-1 associated adult T-cell leukemia/lymphoma presenting outside of Japan. Blood (ASH Annual Meeting Abstracts) 2012; 120.
32. Bhatt S, Ashlock BM, Natkunam Y, Sujoy V, Chapman JR, Ramos JC, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood. 2013;122(7):1233- 42. doi:10.1182/blood-2013-01- 481713.
33. Cerny-Reiterer S SK, Juliana S, et al. Identification of the Ki-1 antigen (CD30) as a novel marker and potential therapeutic target in neoplastic mast cells in advanced systemic mastocytosis. Blood (ASH Annual Meeting Abstracts) 2013; 122 (21).
34. Falini B, Flenghi L, Fedeli L, Broe MK, Bonino C, Stein H, et al. In vivo targeting of Hodgkin and Reed- Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence. Br J Haematol. 1992;82(1):38-45.
35. Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H, et al. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet. 1992;339(8803):1195- 6.
36. Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard JP, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008;111(4):1848-54. doi:10.1182/blood-2007-07-099317. (Pubitemid 351451492)
37. Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007;25(19):2764-9. doi:10.1200/JCO.2006.07.8972. (Pubitemid 47123185)
38. Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146(2):171-9. doi:10.1111/j.1365-2141.2009.07740.x.
39. Duvic M, Reddy SA, Pinter-Brown L, Korman NJ, Zic J, Kennedy DA, et al. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res. 2009;15(19):6217-24. doi:10.1158/1078-0432.CCR-09-0162.
40. Cerveny CG, Law CL, McCormick RS, Lenox JS, Hamblett KJ, Westendorf LE, et al. Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics. Leukemia. 2005;19(9):1648-55. doi:10.1038/sj.leu.2403884. (Pubitemid 43090411)
41. Blum KA, Jung SH, Johnson JL, Lin TS, Hsi ED, Lucas DM, et al. Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcgammaRIIIa-158 V/F polymorphism. Ann Oncol. 2010;21(11):2246-54. doi:10.1093/annonc/mdq211.
42. Lawrence CEHP, Zalevsky J, et al. XmAbTM2513, an Fc engineered humanized anti-CD30 monoclonal antibody, has potent in vitro and in vivo activities, and has the potential for treating hematologic malignancies. Blood (ASH Annual Meeting Abstracts). 2007;110:2340.
43. Blum KA SM, Fung H, et al. Phase I study of an anti- CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: safety, pharmacokinetics (PK), immunogenicity, and efficacy. ASCO Annu Meet (Abstracts). 2009;27:8531.
44. Zhukovsky ERA, von Tesckow B, et al. A Phase I study of an anti-CD30 x anti-CD16A bispecific tandab antibody, AFM13, in patients with relapsed or refractory Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts). 2013;122:5116.
45. Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaecker K, Fischer T, et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine- 131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol. 2005;23(21):4669-78. doi:10.1200/JCO.2005.09.098. (Pubitemid 46224069)
46. Oki Y, Younes A. Brentuximab vedotin in systemic Tcell lymphoma. Expert Opin Biol Ther. 2012;12(5):623-32. doi:10.1517/14712598.2012.670216.
47. Katz J, Janik JE, Younes A. Brentuximab Vedotin (SGN-35). Clin Cancer Res. 2011;17(20):6428-36. doi:10.1158/1078-0432.CCR-11-0488.
48. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458-65. doi:10.1182/blood- 2003-01-0039. (Pubitemid 36988057)
49. .•• Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-21. doi:10.1056/NEJMoa1002965. This article describes the safety and initial clinical activity of brentuximab vedotin in patients with CD30+ lymphomas.
50. Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012;18(1):248-55. doi:10.1158/1078-0432.CCR-11-1425.
51. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-9. doi:10.1200/JCO.2011.38.0410.
52. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-6. doi:10.1200/JCO.2011.38.0402.
53. von Geldern G, Pardo CA, Calabresi PA, Newsome SD. PML-IRIS in a patient treated with brentuximab. Neurology. 2012;79(20):2075-7. doi:10.1212/WNL. 0b013e3182749f17.
54. Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348- 56. doi:10.1016/S1470-2045(13)70501-1.
55. Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, et al. Brentuximab Vedotin in patients aged 60 years or older with relapsed or refractory CD30+ lymphomas: a Retrospective Evaluation of Safety and Efficacy. Leuk Lymph. 2013. doi:10.3109/10428194.2013.876496.
56. Evens AM HP, Advani RH, et al. Sequential brentuximab vedotin (BV) and adriamycin, vinblastine, and dacarbazine (AVD) for older patients with untreated hodgkin lymphoma (HL): preliminary toxicity findings from a phase II window study. Haematologica (9th International Symposium on Hodgkin Lymphoma Abstracts). 2013;98(supplement no. 2):26.
57. Abramson JS HE, Joyce R, et al. Brentuximab vedotin plus AVD as initial therapy of non-bulky limited stage classical Hodgkin lymphoma: interim analysis of an ongoing phase II trial. Haematologica (9th International Symposium on Hodgkin Lymphoma Abstracts) 2013; 90 supplement no. 2.
58. Gopal AK CR, Smith SE, et al. Three-year follow-up data and characterization of long-term remissions from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts). 2013;122(21):4382.
59. Gopal AK, Ramchandren R, O'Connor OA, Berryman RB, Advani RH, Chen R, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120(3):560-8. doi:10.1182/blood-2011-12-397893.
60. Jacobsen ED AR, Oki Y, et al. A Phase 2 study of brentuximab Vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results. Blood (ASH Annual Meeting Abstracts) 2012; 120.
61. Bartlett NL SJ, Oki Y, et al. A Phase 2 study of brentuximab Vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other Bcell lymphomas. Blood (ASH Annual Meeting Abstracts) 2013; 122 (21).
62. Duvic M TM, Clos AL, et al. Phase II trial of brentuximab Vedotin for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders. Blood (ASH Annual Meeting Abstracts) 2013; 122 (21).
63. Moskowitz AJ SH, Gerecitano J, et al. PET adapted sequential salvage therapy with brentuximab vedotin and augmented ICE for trasnplant eligible patient with relapsed and refractory Hodgkin lymphoma. Haematologica (9th International Symposium on Hodgkin Lymphoma Abstracts) 2013; 98 (2).
64. Deutsch YE, Tadmor T, Podack ER, Rosenblatt JD. CD30: an important new target in hematologic malignancies. Leuk Lymph. 2011;52(9):1641-54. doi:10.3109/10428194.2011.574761.